Relugolix Therapy Shows Low Pregnancy Risk
Women using this fibroid treatment may experience a 1.2% annual pregnancy rate, making physician guidance essential.
Updated on Oct. 30, 2026 in Women’s Health
Live Poll
Would you rely on a medication for contraception if it was not primarily approved for that purpose?
The SERENE clinical trial found that women using once-daily relugolix combination therapy for conditions like uterine fibroids experienced a 1.2% pregnancy rate over one year. These findings from the 2026 study provide data on the contraceptive efficacy of this treatment for women aged 18 to 50.
Why it matters
For women managing uterine fibroids or endometriosis, understanding the contraceptive profile of treatment options is essential for planning and care. This research clarifies the pregnancy risk associated with this therapy, helping patients and providers discuss effective family planning during treatment.
The SERENE trial followed 981 women aged 18 to 50 using relugolix combination therapy, resulting in a cumulative 1-year pregnancy rate of 1.2%. While these figures provide initial insight, long-term outcomes regarding bone mineral density health remain subject to ongoing analysis.
The players
American Society for Reproductive Medicine
A professional medical organization that sets standards and disseminates research in reproductive health and fertility.
The details
Relugolix combination therapy functions by suppressing the release of luteinizing hormone and follicle-stimulating hormone. This hormonal suppression reduces the production of ovarian estradiol and progesterone, which is intended to manage fibroids and endometriosis. Throughout the 13 treatment cycles, researchers monitored participants for bone mineral density changes, as 193 individuals discontinued use due to bone loss exceeding 3%.
Timeline
The clinical data was highlighted at the 2026 American Society for Reproductive Medicine meeting in October.
Health Landscape
The SERENE clinical trial represents an evolving approach to managing reproductive health conditions like uterine fibroids. It sits within a growing body of research aiming to balance symptom management with the contraceptive implications of modern hormonal therapies.
If you are using or considering this medication, it is important to discuss your family planning needs with your physician. Because individual risks regarding bone mineral density and contraceptive efficacy can vary, regular check-ins with your care team are essential to monitor your treatment.
The takeaway
Understanding the efficacy of your treatment is a key step in managing chronic conditions while maintaining your reproductive health goals. Talk to your doctor to review the full safety profile and potential side effects before deciding on a long-term treatment plan.
Further reading
Learn more about reproductive health developments in Women’s Health.
Source note: This article includes information reported by Medscape.
Live Poll
Would you rely on a medication for contraception if it was not primarily approved for that purpose?
